Parallax Volatility Advisers
ALNY icon

Parallax Volatility Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parallax Volatility Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-54,800
Closed -$12.9M – 1539
2024
Q4 		$12.9M Sell
54,800
-58,500
-52% -$15.4M 0.03% 484
2024
Q3 		$31.2M Buy
+113,300
New +$29.5M 0.06% 239
2020
Q4 		– Sell
-55,000
Closed -$8.01M – 2275
2020
Q3 		$8.01M Buy
55,000
+6,800
+14% +$966K 0.01% 1105
2020
Q2 		$7.14M Buy
48,200
+42,600
+761% +$5.74M 0.01% 933
2020
Q1 		$613K Sell
5,600
-6,400
-53% -$739K ﹤0.01% 1646
2019
Q4 		$1.38M Buy
+12,000
New +$1.2M ﹤0.01% 1384
2018
Q4 		– Sell
-10,000
Closed -$875K – 2873
2018
Q3 		$875K Buy
+10,000
New +$1.01M ﹤0.01% 1309
2018
Q1 		– Sell
-10,000
Closed -$1.27M – 2187
2017
Q4 		$1.27M Buy
+10,000
New +$1.26M ﹤0.01% 1094

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's ALNY Position: Q1 2025 in Review

Parallax Volatility Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 23,161 shares — an estimated $5.45M sold.

Parallax Volatility Advisers first reported a position in ALNY in Q2 2015 and held it in 17 quarters. The position peaked at $7.3M in Q3 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Parallax Volatility Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 23,161 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $5.45M.
  • Parallax Volatility Advisers first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 17 quarters.
  • Parallax Volatility Advisers's Alnylam Pharmaceuticals position peaked at $7.3M in Q3 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Parallax Volatility Advisers's 13F filing for Q1 2025, filed 15 May 2025.